Jingxin Pharmaceutical Files Hong Kong IPO for Dual Listing Strategy
Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) has submitted its IPO prospectus to the Hong Kong Stock...
SHE: 002020
National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate
The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than...
Jingxin Pharmaceutical’s Didaxini Gains NMPA Approval as Category 1 Drug
Jingxin Pharmaceutical Co., Ltd (SHE: 002020), a Chinese pharmaceutical company, has announced that it has...
Jingxin Pharmaceutical Receives NMPA Approval for JBPOS0101 and JX7002 Trials
Jingxin Pharmaceutical Co., Ltd (SHE: 002020) announced that it has received clinical trial approvals from...